Table 2.
P values for treatment-by-subgroup interaction analyses
| Q6M | Q3M | |
|---|---|---|
| Swollen joint count | 0.402 | 0.553 |
| Tender joint count | 0.979 | 0.696 |
| CRP | 0.815 | 0.946 |
| ESR | 0.692 | 0.696 |
| Glucocorticoid use | 0.174 | 0.075 |
| RF status | 0.266 | 0.454 |
| Anti-CCP antibodies | 0.193 | 0.029 |
| Baseline mTSS | 0.587 | 0.154 |
| Baseline ES | 0.241 | 0.063 |
CCP, cyclic citrullinated peptide; CRP, C reactive protein; ES, bone erosion score; ESR, erythrocyte sedimentation rate; mTSS, modified total Sharp score; Q3M, denosumab 60 mg every 3 months; Q6M, denosumab 60 mg every 6 months; RF, rheumatoid factor.